Leukogram and Antibody Levels after Vaccination Against Porcine Circovirus Pcv2

Piglets from a porcine circovirus type 2 (PCV2) stable farm of low and high levels of maternally derived antibodies (MDA) against PCV2 were vaccinated either with a whole virus type or a PCV2 ORF2 antigen-based commercial subunit vaccine at three weeks of age. Two non-vaccinated groups served as low and high MDA positive controls. At four weeks post vaccination, all piglets were challenged with a PCV2d-2 type virus strain and were checked for parameters related to vaccine protection over a four-week observation period. MDA levels evidently impacted the outcome of the PCV2d-2 challenge in non-vaccinated animals, while it did not have a significant effect on vaccine-induced protection levels. The humoral immune response developed faster in the whole virus vaccinates than in the subunit vaccinated pigs in the low MDA groups. Further, high MDA levels elicited a stronger negative effect on the vaccine-induced humoral immune response for the subunit vaccine than for the whole virus vaccine. The group-based oral fluid samples and the group mean viraemia and faecal shedding data correlated well, enabling this simple, and animal welfare-friendly sampling method for the evaluation of the PCV2 viral load status of these nursery piglets.

Download Full-text

Immune responses induced by a combined vaccination with a recombinant chimera of Mycoplasma hyopneumoniae antigens and capsid virus-like particles of porcine circovirus type 2

BMC Veterinary Research ◽

10.1186/s12917-020-02560-8 ◽

2020 ◽

Vol 16 (1) ◽

Author(s):

Yu Tao ◽

Rui Yang ◽

Jianhong Shu ◽

Wenqian Zheng ◽

Jian Chen ◽

...

Keyword(s):

Immune Responses ◽

Mycoplasma Hyopneumoniae ◽

Porcine Circovirus Type ◽

Porcine Circovirus Type 2 ◽

Negative Control ◽

Porcine Circovirus ◽

Protein Antigens ◽

Virus Like Particles ◽

Antibody Levels

Abstract Background Mycoplasma hyopneumoniae (Mhp) and porcine circovirus type 2 (PCV2) are two important pathogens causing Mycoplasma pneumonia of swine (MPS) and porcine circovirus diseases and porcine circovirus-associated diseases (PCVDs/PCVADs), respectively, and resulted in considerable economic loss to the swine industry worldwide. Currently, vaccination is one of the main measures to control these two diseases; however, there are few combination vaccines that can prevent these two diseases. To determine the effect of combination immunization, we developed capsid-derived (Cap) virus-like particles (VLPs) of PCV2 and a new recombinant chimera composed of the P97R1, P46, and P42 antigens of Mhp. Then we investigated the immune responses induced by the immunization with this combination vaccine in mice and piglets. Results The high level antibodies against three protein antigens (P97R1, P46, and P42 of Mhp) were produced after immunization, up to or higher than 1:400,000; the antibody levels in Pro group continuously increased throughout the 42 days for all the antigens tested. The lymphocyte proliferative response in PCV2 group was stronger than that in PBS, VP, Mhp CV in mice. The antibody levels for Cap remained stable and reached the peak at 35 DAI. The IFN-γ and IL-4 in sera were significantly enhanced in the Pro group than that in the negative control-VP group on Day 14 and 28 post-the first immunization in piglets. Conclusions Above all, the combination immunization could induce humoral and cellular immune responses against all four antigens in mice and piglets. Therefore, our approach is a simple and effective vaccination strategy to protect pigs against MPS and PCVD/PCVAD.

Download Full-text

The effects of sow viremia and maternal antibodies in porcine circovirus 2 on viral infection and weight of piglets

Arquivo Brasileiro de Medicina Veterinária e Zootecnia ◽

10.1590/1678-41625917 ◽

2014 ◽

Vol 66 (2) ◽

pp. 405-410 ◽

Cited By ~ 1

Author(s):

P.F. Gerber ◽

F.M. Garrocho ◽

Z.I.P. Lobato

Keyword(s):

Viral Load ◽

Neutralizing Antibodies ◽

Maternal Antibodies ◽

Porcine Circovirus ◽

Serum Samples ◽

Blood Samples ◽

Milk Samples ◽

Newborn Piglets ◽

Porcine Circovirus 2 ◽

Antibody Levels

The aim of this study was to characterize the porcine circovirus 2 (PCV2) infections in farrowing sows and to evaluate an association with piglet viremia and weight. Twenty sows and 100 newborn piglets were studied. Colostrum and serum of the sows were obtained on the day of parturition. Milk samples were collected on day 20 postpartum. Blood samples were taken and the piglets were weighed on days 1, 20, 42, 63 and 84 postpartum. Colostrum, milk and serum were evaluated for PCV2 DNA load. Serum was evaluated for neutralizing antibodies. PCV2 DNA was found in 17/20 serum samples, 14/20 colostrum samples and 11/20 milk samples. On day 1 postpartum 29% of piglets were viremic. PCV2 viral load ranged from 3.02 to 6.75 log10 copies/mL considering all sampled days. There was no correlation between sow viremia, antibody levels or PCV2 load in colostrum and piglet viremia on day 1 postpartum. The PCV2 load in colostrum and milk was associated with viremia in piglets from weaning to 84 days postpartum. Piglets' PCV2 viremia and viral load could not be associated with weight throughout this study.

Download Full-text

Porcine circovirus as a possible cause of postweaning wasting in pigs in Switzerland

Schweizer Archiv für Tierheilkunde ◽

10.1024/0036-7281.146.10.461 ◽

2004 ◽

Vol 146 (10) ◽

pp. 461-469 ◽

Cited By ~ 4

Author(s):

S. Staebler ◽

E. Buergi ◽

B. Litzenberger ◽

K. McCullough ◽

I. McNair ◽

...

Keyword(s):

Porcine Circovirus ◽

Possible Cause

Download Full-text

One Year Outcome After Cardiac Transplantation Is Not Compromised by Elevated Pretransplant Panel Reactive Antibody Levels in Patients With Ventricular Assist Devices

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(97)84972-8 ◽

1998 ◽

Vol 31 (2) ◽

pp. 290A

Author(s):

S Trehan

Keyword(s):

Cardiac Transplantation ◽

Ventricular Assist Devices ◽

Ventricular Assist ◽

Assist Devices ◽

Panel Reactive Antibody ◽

One Year ◽

Antibody Levels ◽

Reactive Antibody

Download Full-text

Prevalence and Induction of Circulating Antibodies against Recombinant Staphylokinase

Thrombosis and Haemostasis ◽

10.1055/s-0038-1642396 ◽

1994 ◽

Vol 71 (01) ◽

pp. 129-133 ◽

Cited By ~ 33

Author(s):

P J Declerck ◽

S Vanderschueren ◽

J Billiet ◽

H Moreau ◽

D Collen

Keyword(s):

Intravenous Administration ◽

Human Subjects ◽

Microtiter Plates ◽

Staphylococcus Aureus Bacteremia ◽

Alternative Agent ◽

Antibody Titers ◽

Potential Alternative ◽

Circulating Antibodies ◽

Low Levels ◽

Antibody Levels

SummaryStreptokinase (SK) is a routinely used thrombolytic agent but it is immunogenic and allergenic; staphylokinase (STA) is a potential alternative agent which is under early clinical evaluation. The comparative prevalence of antibodies against recombinant STA (STAR) and against SK was studied in healthy subjects and their induction with intravenous administration in small groups of patients.Enzyme-linked immunosorbent assays, using microtiter plates coated with STAR or SK and calibration with affinospecific human antibodies, revealed 2.1 to 65 μg/ml (median 11 μg/ml) anti-STAR antibodies and 0.9 to 370 μg/ml (median 18 μg/ml) anti-SK antibodies (p <0.001 vs anti-STAR antibodies) in plasma from 100 blood donors, with corresponding values of 0.6 to 100 μg/ml (median 7.1 μg/ml) and 0.4 to 120 μg/ml (median 7.3 μg/ml), respectively, in 104 patients with angina pectoris. Three out of 17 patients with Staphylococcus aureus bacteremia had significantly increased anti-STAR antibody levels (150, 75 and 75 μg/ml), and STAR neutralizing activities (2.2, 3.6 and 4.1 μg STAR neutralized per ml plasma, respectively). In 6 patients with acute myocardial infarction, given 10 mg STAR intravenously over 30 min, median anti-STAR antibody levels were 3.5 μg/ml at baseline, 2.9 μg/ml at 6 to 8 days and 1.2 μg/ml at 2 to 9 weeks, with median corresponding titers of STAR neutralizing activity at 2 to 9 weeks of 42 μg/ml plasma. Conversely, in 5 patients treated with 1,500,000 units SK over 60 min, median anti-SK antibodies increased from 2.9 μg/ml at baseline to 360 μg/ml at 5 to 10 days, with corresponding median SK neutralizing activities of 13 μg/ml. Antibodies against STAR did not cross-react with SK and vice versa.Plasma from human subjects contains low levels of circulating antibodies against recombinant staphylokinase, and intravenous administration of this compound boosts antibody titers. These antibodies do however not cross-react with streptokinase, whereby the use of these two immunogenic thrombolytic agents would not be mutually exclusive.

Download Full-text

Management of Haemophilia A with Antibodies - The Effect of Combined Treatment with Factor VIII, Hydrocortisone and Cyclophosphamide

Thrombosis and Haemostasis ◽

10.1055/s-0038-1660131 ◽

1985 ◽

Vol 54 (04) ◽

pp. 776-779 ◽

Cited By ~ 13

Author(s):

U Hedner ◽

L Tengborn

Keyword(s):

Factor Viii ◽

Combined Treatment ◽

Factor Ix ◽

Treatment Schedule ◽

High Antibody ◽

Anamnestic Response ◽

Short Intervals ◽

Low Responders ◽

Antibody Levels ◽

High Responders

SummaryImmune tolerance has by several methods been induced in haemophiliacs with antibodies. A conversion of “high responders” into “low responders” was previously reported after repeated moderate factor IX doses over periods of 7-10 days in combination with cyclophosphamide and steroids in two patients with haemophilia B and inhibitors. This paper reports similar results in a heamophilia A patient by giving factor VIII, cyclophosphamide, and steroids during relatively short periods of time (7-8 days). The anamnestic response markedly decreased already following the first treatment and never exceeded a level of 1 u/ml (˜ 3 BU/ml) even when boosted with ordinary factor VIII doses for only 3 days. It is concluded that the markedly decreased secondary antibody response is most probably the result of factor VIII given at short intervals (twice a day) for periods of up to about one week when given in combination with cyclophosphamide and steroids. The same effect may be achieved by other methods. The treatment schedule suggested in the present paper is, however, simple and avoids long periods of high antibody levels. Furthermore, the total factor VIII dose used is lower than suggested in most other treatment schedules, which makes the treatment substantially less expensive.

Download Full-text